EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series
EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27th at 4:00 PM ET
6月27日星期四将与enVVeno Medical首席执行官Robert Berman进行现场视频直播。th美国东部时间下午4:00
IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Thursday, June 27, 2024 at 4:00 PM ET.
加利福尼亚州尔湾/ACCESSWIRE/2024年6月25日/enVVeno Medical Corporation（NASDAQ: NVNO）（"enVVeno"或"本公司"）是一家为静脉疾病治疗设立新标准的公司。今天宣布，enVVeno Medical首席执行官Robert Berman将于2024年6月27日下午4点参加虚拟投资者收盘钟系列活动。
As part of the event, Mr. Berman will discuss the Company's recently reported positive interim venous ulcer healing data showing significant improvement from the Company's SAVVE U.S. pivotal trial for the VenoValve. He will also highlight key safety and efficacy data reported to date from the SAVVE trial and outline the timeline for expected approval the VenoValve.
作为活动的一部分，Berman先生将会讨论公司最近公布的有关SAVVE美国关键试验对VenoValve的中期治疗静脉溃疡数据的正面展示，也会突出展示来自SAVVE试验到目前为止报告的重要安全和有效数据，并概述VenoValve预期批准的时间表。
In addition to the prepared remarks, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.
除了准备好的讲话外，还将举行现场问答环节。Berman先生将在规定时间内尽可能回答尽可能多的问题。
A live video webcast of the presentation will be available on the Events page of the Company's website (). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
演示的视频实况将可在本公司网站的事件页面上得到。两小时后，再次播放的视频实况将可被播放，并保持开放90天。
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently performing the final testing necessary to seek approval for the enVVe pivotal trial.
关于enVVeno Medical Corporation
enVVeno Medical（NASDAQ: NVNO）是一家总部位于加利福尼亚尔湾的后期临床阶段医疗器械公司，致力于推进改善静脉疾病治疗标准的创新生物义肢（基于组织）。该公司的主要产品VenoValve是一种首创的手术性替代静脉瓣膜，用于治疗深静脉慢性静脉不全（CVI）。公司还正在开发一种非手术性、经导管的替代静脉瓣膜，用于治疗深静脉CVI，称为enVVe。当腿部静脉内的瓣膜受损时，CVI发生了，导致血液倒流（反流），血液在下肢积聚，静脉内压力升高（静脉高压），在严重情况下形成难以愈合和变成慢性的静脉溃疡。无论是VenoValve还是enVVe都是为了充当单向阀门，以帮助推动血液向上运输，返回心脏和肺脏。目前VenoValve正在接受SAVVE美国关键研究评估，公司目前正在进行最后的测试，以寻求enVVe关键试验的批准。
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(833) 475-8247
投资者联系方式：
Jenene Thomas，JTC团队LLC
NVNO@jtcir.com
(833) 475-8247
SOURCE: enVVeno Medical Corporation
来源：enVVeno Medical Corporation